PMID- 38243286
OWN - NLM
STAT- MEDLINE
DCOM- 20240122
LR  - 20240202
IS  - 1477-7827 (Electronic)
IS  - 1477-7827 (Linking)
VI  - 22
IP  - 1
DP  - 2024 Jan 20
TI  - Serum erythropoietin level is increased during stimulation for IVF but not in 
      OHSS.
PG  - 14
LID - 10.1186/s12958-023-01178-3 [doi]
LID - 14
AB  - BACKGROUND: Erythropoietin (Epo) is a potent vascular growth factor that induces 
      angiogenesis and antiapoptotic signalling. We investigated whether the 
      development of numerous follicles and corpora lutea during in vitro fertilization 
      (IVF) cycle affects circulating Epo levels and further, if Epo could be used as a 
      novel marker for ovarian hyperstimulation syndrome (OHSS). METHODS: 24 women were 
      included in the uncomplicated IVF group and 35 women in the OHSS group. Repeated 
      blood samples from both groups were analysed for Epo, progesterone, blood 
      haemoglobin, and creatinine. Follicular fluid from the IVF group was analysed for 
      Epo and progesterone. Repeated measure analysis was performed for the variables 
      and circulating Epo levels were compared between the IVF group and early OHSS. 
      Furthermore, related growth factors, vascular endothelial growth factor (VEGF) 
      and hypoxia-inducible factor-1 (HIF-1) were analysed from subgroup of women to 
      test for correlation with Epo. RESULTS: During IVF, circulating Epo increased 
      from natural mid-luteal phase to stimulated mid-luteal phase (median 9.5; 95% CI 
      7.2-13.4 IU/L and 12.5; 10.3-13.4 IU/L; p = 0.003). In cycles resulting in 
      pregnancy, Epo level decreased 14 days after oocyte pick-up (OPU) and remained 
      low thereafter. In cycles not resulting in pregnancy, Epo level increased again 
      35 days after OPU. Follicle fluid Epo concentration was 1.5 times higher than the 
      serum concentration (median 15.4; 95% CI 10.4-19.2 IU/L vs. 10.2; 8.8-12.7; p = 
      0.006). There was no difference in circulating Epo concentration between early 
      OHSS and uncomplicated IVF. Circulating Epo did not correlate with VEGF or HIF-1. 
      CONCLUSIONS: Circulating Epo levels fluctuate during IVF cycle. We hypothesise 
      this may suggest Epo's involvement in ovarian physiology and angiogenesis. 
      However, Epo was not a clinical marker for OHSS.
CI  - (c) 2024. The Author(s).
FAU - Rekola, Merituuli
AU  - Rekola M
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital and 
      University of Helsinki, PO Box 140, Haartmaninkatu 2, Helsinki, 00290, Finland.
FAU - Korhonen, Kati
AU  - Korhonen K
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital and 
      University of Helsinki, PO Box 140, Haartmaninkatu 2, Helsinki, 00290, Finland.
FAU - Unkila-Kallio, Leila
AU  - Unkila-Kallio L
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital and 
      University of Helsinki, PO Box 140, Haartmaninkatu 2, Helsinki, 00290, Finland.
FAU - Alfthan, Henrik
AU  - Alfthan H
AD  - HUSLAB, Helsinki University Hospital, Topeliuksenkatu 32, Helsinki, 00029, 
      Finland.
FAU - Stefanovic, Vedran
AU  - Stefanovic V
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital and 
      University of Helsinki, PO Box 140, Haartmaninkatu 2, Helsinki, 00290, Finland.
FAU - Tiitinen, Aila
AU  - Tiitinen A
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital and 
      University of Helsinki, PO Box 140, Haartmaninkatu 2, Helsinki, 00290, Finland.
FAU - Mikkola, Tomi S
AU  - Mikkola TS
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital and 
      University of Helsinki, PO Box 140, Haartmaninkatu 2, Helsinki, 00290, Finland.
FAU - Savolainen-Peltonen, Hanna
AU  - Savolainen-Peltonen H
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital and 
      University of Helsinki, PO Box 140, Haartmaninkatu 2, Helsinki, 00290, Finland. 
      hanna.savolainen-peltonen@hus.fi.
LA  - eng
PT  - Journal Article
DEP - 20240120
PL  - England
TA  - Reprod Biol Endocrinol
JT  - Reproductive biology and endocrinology : RB&E
JID - 101153627
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 4G7DS2Q64Y (Progesterone)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - *Ovarian Hyperstimulation Syndrome/etiology
MH  - Vascular Endothelial Growth Factor A
MH  - Progesterone
MH  - Fertilization in Vitro/methods
MH  - *Erythropoietin
MH  - Ovulation Induction/adverse effects
PMC - PMC10799481
OTO - NOTNLM
OT  - Angiogenesis
OT  - Early pregnancy
OT  - Erythropoietin
OT  - In vitro fertilization
OT  - Ovarian hyperstimulation syndrome
COIS- HS-P has been a member of the advisory board of Ferring Pharmaceuticals and a 
      consultant to Merck and Orion.
EDAT- 2024/01/20 05:42
MHDA- 2024/01/22 06:43
PMCR- 2024/01/20
CRDT- 2024/01/19 23:41
PHST- 2023/10/12 00:00 [received]
PHST- 2023/12/20 00:00 [accepted]
PHST- 2024/01/22 06:43 [medline]
PHST- 2024/01/20 05:42 [pubmed]
PHST- 2024/01/19 23:41 [entrez]
PHST- 2024/01/20 00:00 [pmc-release]
AID - 10.1186/s12958-023-01178-3 [pii]
AID - 1178 [pii]
AID - 10.1186/s12958-023-01178-3 [doi]
PST - epublish
SO  - Reprod Biol Endocrinol. 2024 Jan 20;22(1):14. doi: 10.1186/s12958-023-01178-3.